🇺🇸

IPO Capital Markets

· daily

US IPO Pipeline SEC S-1 Filings — August 13, 2026

The IPO Pipeline stream for August 13, 2026, features two distinct capital markets events: Rocket Lab's transformative S-4 merger with Iridium Communications and BayFirst Financial's S-1 resale registration. Rocket Lab's acquisition is a high-materiality strategic consolidation, creating a vertically integrated space company with a global satellite network, while BayFirst's filing is a routine resale registration with no new capital raised. Both filings signal active capital markets activity, with Rocket Lab's deal representing a significant catalyst for the space sector and BayFirst's registration indicating potential overhang from a recent private placement. The absence of traditional IPO pricing data in these filings limits period-over-period trend analysis, but the strategic and structural details provide actionable insights for investors.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 12, 2026

The IPO pipeline for August 12, 2026, shows a mixed landscape dominated by pre-revenue biotech, cash-constrained fintech, and SPAC mergers with space-tech and data-analytics targets. Six filings were analyzed: two S-1s (Onconetix, BirchBioMed) and two S-1s with financial data (Fast Finance Pay Corp, SharonAI), plus two S-4 SPAC combinations (Space-Eyes, Mobilewalla). Period-over-period data reveals diverging financial health: Onconetix shows zero revenue momentum and a $135.4M accumulated deficit, while Fast Finance Pay Corp turned a $3.2M loss into $186K net income YoY but still burns cash. Space-Eyes and Mobilewalla represent high-risk/high-reward SPAC targets with $172.5M and $174.9M trust proceeds respectively, but face redemption risk. BirchBioMed's blank S-1 (no financials, no business description) signals a hollow or early-stage filing. The overarching theme is capital starvation in early-stage healthcare and fintech, contrasted by well-funded SPAC vehicles chasing space and data monetization.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 11, 2026

The IPO pipeline digest for August 11, 2026, reveals a subdued but active registration environment, with three S-1 filings totaling significant share registrations but no primary capital raises for the issuers. Aura Consolidated Group, Inc. leads with a massive 143.3 million share resale registration, signaling potential near-term selling pressure from existing stockholders, while FTC Solar, Inc. files for a $20 million at-the-market offering amid severe financial distress, including a going concern warning and a working capital deficit of $7.9 million. YouneeqAI Technical Services, Inc. registers 11.7 million shares for resale at $1.00 per share, targeting OTCQB listing, but its complex history of six name changes and failed business pivots raises governance concerns. Period-over-period comparisons are limited as these are initial registrations, but the absence of forward-looking guidance and insider activity across all three filings suggests a cautious, compliance-driven pipeline rather than a growth-oriented one. The overarching theme is a bifurcated pipeline: one established foreign issuer seeking US market access, one distressed solar company desperate for liquidity, and one micro-cap with a checkered past attempting a fresh start.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 10, 2026

The IPO pipeline on August 10, 2026, is overwhelmingly dominated by SPAC registrations, with 5 of 10 filings being blank-check companies (Inflection Point VIII, Eaglesky, JATT III, Gores Holdings XII, GigCapital10) seeking to raise a combined $320M+ in gross proceeds. This SPAC wave signals renewed sponsor confidence in the de-SPAC market, though the sector focus remains broad and largely undisclosed. Notable is the absence of traditional operating company IPOs, with only Curis Inc. (a follow-on offering) and ClearOne Inc. (an early-stage S-1) representing non-SPAC equity raises. A significant cross-current is the business combination activity from Hannon Armstrong and MN8 Energy, both filed via S-4 registration statements, indicating ongoing M&A in the energy and infrastructure sectors. The most actionable insight is the Eaglesky Acquisition Corp filing, which explicitly excludes Chinese targets despite management's China ties, creating a unique risk/reward profile. Overall, the pipeline reflects a market cautiously re-embracing SPACs while traditional IPO windows remain narrow, with no period-over-period trends available as all filings are initial registrations.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 07, 2026

The August 7, 2026 IPO pipeline is dominated by early-stage and high-risk filings, with 5 out of 10 filings representing blank-check companies (SPACs) or pre-revenue entities, signaling a surge in speculative capital formation. A critical theme is the prevalence of dilutive structures: My Size, Inc.'s ELOC agreement and Veradermics' resale offering of 40.6% of outstanding shares highlight significant shareholder dilution risks. The Fox Corp-Roku S-4 merger stands out as the sole high-quality, actionable event, offering a unique arbitrage opportunity with a fixed exchange ratio and cash component. Period-over-period data is sparse across filings, but insider activity and forward-looking statements reveal a cautious sentiment, with multiple companies facing Nasdaq delisting risks and needing substantial funding. The overall pipeline suggests a bifurcated market: high-risk SPACs and pre-revenue biotechs seeking capital, versus a transformative media merger with clear valuation metrics.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 06, 2026

Today's IPO pipeline filings present a mixed landscape of opportunity and risk. Alternus Clean Energy and Rainier Acquisition Corp have filed S-1s, but both lack critical financial data, making immediate assessment impossible. In contrast, Jones Soda Co.'s filing is highly material, revealing a strategic pivot away from its cannabis-infused business due to new federal THC caps, while retaining its hemp-derived beverage line. The overarching theme is regulatory uncertainty in the beverage sector, with Jones Soda's restructuring creating a clear catalyst. Investors should focus on the upcoming SEC review for all three, but particularly watch for Jones Soda's financials and the outcome of its licensing deal.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 05, 2026

The IPO pipeline for August 5, 2026, is dominated by two SPAC filings (Gravity Acquisition Corp. and BNB PLUS CORP.) and a highly opaque business combination filing (Criteo Holdings, Inc.), signaling a cautious but active market for blank-check companies. No period-over-period comparisons, insider trading, capital allocation, or forward-looking guidance are available across any of the three filings, as the S-1 and S-4 registrations are initial or incomplete. Gravity Acquisition Corp. provides the most concrete data with a $252.7 million unit offering at $10.00, a 15-month deadline, and sponsor lock-up provisions, but lacks any operational metrics or financial trends. BNB PLUS CORP. and Criteo Holdings offer virtually no actionable financial or strategic details, resulting in high uncertainty and low materiality. The overarching theme is a lack of transparency typical of early-stage IPO filings, with no sector concentration or cross-cutting patterns to exploit. Investors should monitor these filings for subsequent amendments (S-1/A, 8-K) that will provide critical pricing, financial, and business combination details.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 04, 2026

The IPO pipeline for August 4, 2026, is dominated by a single new SPAC registration, Luminous Acquisition, which seeks to raise capital for a blank-check business combination, reflecting continued but measured SPAC activity. The filing shows a mixed sentiment due to the inherent risks of SPAC structures, including warrant redemption terms and expiration of rights if no deal is completed. DuPont de Nemours, while filing an S-4 for a debt exchange offer, is not a new IPO but provides critical context on capital markets activity and corporate financial health, with a sharp YoY swing from net income of $703 million in 2024 to a net loss of $779 million in 2025. The DuPont filing also highlights a 1-for-3 reverse stock split, signaling potential efforts to maintain listing standards or improve share price perception. No insider trading activity or forward-looking guidance was provided in these filings, limiting trend analysis but underscoring the importance of monitoring deal timelines and financial performance. The overall pipeline shows a mix of speculative SPAC issuance and established corporate debt restructuring, with no traditional operating company IPOs in this batch.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 03, 2026

The IPO pipeline for August 3, 2026, is dominated by two blank-check companies (SPACs) filing S-1 registrations: GX Acquisition Corp. III and 1776 Acquisition Corp. Both filings are neutral in sentiment and carry a materiality score of 7/10, reflecting the inherently speculative nature of SPACs with no operating history or identified targets. The filings reveal a common theme of limited working capital, with GX Acquisition Corp. III explicitly stating only ~$1.275 million is available outside the trust to fund operations for 24 months, while 1776 Acquisition Corp. emphasizes a 15% over-allotment option and trust account structure. No period-over-period comparisons, insider trading activity, forward-looking guidance, or capital allocation data are available from these initial filings, as both companies are pre-revenue and pre-operational. The key development is the simultaneous registration of two SPACs, signaling continued market appetite for blank-check vehicles despite regulatory scrutiny and redemption risks. The lack of enriched data fields (period comparisons, insider trades, guidance) limits deep quantitative synthesis, but the structural risks—redemption caps, competition, and potential litigation—are actionable for investors monitoring the SPAC space.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 30, 2026

The IPO pipeline digest for July 30, 2026, reveals a mixed landscape with two new S-1 filings and one routine S-4 filing. Presidio Production Co's S-1 shows strong top-line growth (revenue +15% YoY to $5.0B) and margin expansion (net income +22% YoY to $1.2B), but is tempered by a 7% production decline in its key Oklahoma region, which now contributes 35% of total BOE (down from 40%). Laser Photonics Corp's S-1 highlights significant dilution risk from selling stockholders, including affiliates of placement agent H.C. Wainwright, with no proceeds to the company from share sales. Comcast's S-4 is a routine exchange offer with low materiality. Key period-over-period trends include Presidio's improved operational efficiency (net income growth outpacing revenue growth by 700 bps) and a shift in production mix away from Oklahoma. The most critical development is the potential overhang from Laser Photonics' secondary offering, which could pressure the stock. Portfolio-level patterns show a divergence between capital-intensive energy IPOs (high capex, production risks) and small-cap tech resale filings (dilution risks).

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 29, 2026

The IPO pipeline on July 29, 2026, is dominated by a mix of de-SPAC transactions, direct listings, and distressed capital raises, with a notable concentration in the energy and technology sectors. Key period-over-period trends are absent from most filings due to the lack of historical operating data for pre-revenue or development-stage companies, but several filings reveal severe financial distress—Global Interactive Technologies has a going concern opinion and only ~4 months of cash runway, while Moleculin Biotech warns of capital only into Q1 2027 without the maximum offering. The most critical development is the PBT Land & Minerals business combination, which converts a 75% net overriding royalty interest into a cost-free 15% royalty, eliminating cost exposure and providing more predictable cash flow, backed by a $71.2M backstop from SoftVest and Horizon Kinetics. Insider activity is minimal across filings, but the lack of insider selling in the PBT deal and the presence of a backstop commitment signal institutional confidence. Portfolio-level patterns include a trend toward alternative listing methods (direct listing, rights offerings) and a high proportion of companies with going concern or liquidity warnings, suggesting a bifurcated pipeline with both high-quality asset conversions and distressed issuers.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 28, 2026

Both filings in today's IPO pipeline digest reveal a stark pattern of micro-cap distress, with two Nasdaq-listed companies (Polar Power and Sadot Group) filing S-1 registration statements for resale of common stock amid severe financial challenges. Period-over-period data shows Polar Power's stockholders' equity improved from ~$0.1M (Dec 2025) to $2.3M (Mar 2026), a massive 2,200% QoQ increase, yet still below the $2.5M minimum, while Sadot Group claims equity has been restored to over $7M through an acquisition and other measures, though audited financials are pending. Both companies face Nasdaq non-compliance letters—Polar Power received one on May 1, 2026, and Sadot on May 5, 2026—and both carry going concern qualifications from their auditors. The most critical development is the operational instability at Polar Power, which was evicted from its headquarters on May 19, 2026, and lost two independent directors, signaling deep governance and liquidity crises. The portfolio-level theme is that these are not traditional IPOs but rather distressed resale registrations, where selling stockholders (including a committed equity facility provider) seek to exit positions, making these filings a red flag for retail investors rather than a pipeline of new growth stories.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 27, 2026

The IPO Pipeline digest for July 27, 2026, reveals a bifurcated market: one established financial firm (Jones Financial) is restructuring its capital structure without a public listing, while two smaller, high-risk entities (AIxCrypto and OppFi) pursue transformative transactions to access public markets or expand via M&A. Period-over-period trends are limited as these are initial filings, but forward-looking data and transaction details highlight significant execution risk. AIxCrypto, with no material revenue, is pivoting to RWA tokenization and Embodied AI, relying on a $50 million equity facility—a high-risk, high-reward play. OppFi's merger with BNCC offers a fixed exchange ratio that creates valuation uncertainty for BNCC shareholders, though it targets a tax-free reorganization. No insider trading activity was reported in any filing, and capital allocation data is sparse, underscoring the early-stage nature of these deals. The overarching theme is capital structure transformation, with materiality ranging from moderate (Jones) to very high (OppFi), but all carry execution and regulatory risks.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 24, 2026

The IPO pipeline on July 24, 2026, is dominated by two $150 million SPAC IPOs (Bluerock Acquisition Corp. II and K2 Capital Acquisition Corp. II) and three smaller, higher-risk operating company registrations (INVO Fertility, Powerdyne International, and Isabella Bank Corp's S-4 merger proxy). A key theme is the resurgence of blank-check companies, with two SPACs filing on the same day, signaling renewed sponsor confidence in the SPAC market after a prolonged downturn. However, the quality of the non-SPAC filers is mixed: INVO Fertility shows signs of operational distress (regaining compliance after late filings, a reverse stock split, and a dilutive resale offering), while Powerdyne International acknowledges material weaknesses in internal controls, a major red flag for new public investors. The Isabella Bank S-4 is a merger proxy, not a capital raise, and is the only filing with a clear, near-term catalyst (a shareholder vote). No period-over-period financial trends are available as all companies are pre-revenue or newly public, shifting the focus to governance, dilution risk, and deal structure. The most critical development is the simultaneous SPAC filings, which may indicate a broader market appetite for blank-check vehicles, but investors must scrutinize the lack of identified targets and the potential for dilution.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 23, 2026

The IPO pipeline for July 23, 2026, reveals a bifurcated market: one traditional operating company (Syntec Optics) is attempting to go public after resolving severe compliance issues, while two others (Innovative Eyewear and Lyntris) are burdened by weak financial health and governance red flags. AParadise Acquisition Corp. represents the SPAC sector, but its small size and forfeiture of founder shares signal muted sponsor confidence. No period-over-period revenue or margin trends are available across these pre-revenue or pre-IPO entities, but the absence of insider buying and the presence of material weaknesses in internal controls (Lyntris) and out-of-the-money warrants (Innovative Eyewear) suggest cautious investor sentiment. The most critical development is Lyntris's $284.7M debt load and unremediated control weaknesses, which could deter institutional participation. Overall, the pipeline lacks high-quality, growth-stage issuers, indicating a potential lull in new listings.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 22, 2026

The IPO pipeline for July 22, 2026, features two blank-check companies (SPACs) and one de-SPAC merger filing, indicating continued SPAC activity despite regulatory scrutiny. NorthStrive Acquisition Corp I and Pinnacle Acquisition Corp both filed S-1 registrations, targeting $100 million and an undisclosed amount, respectively, with no identified targets. Air Industries Group filed an S-4 for its merger with Tenax Aerospace, a deal that would dilute existing AIRI shareholders to ~4% ownership. No period-over-period trends or insider activity are available as these are initial filings. The SPACs carry high execution risk, while the AIRI merger presents a high-risk, high-reward opportunity with significant dilution. The lack of forward-looking guidance or insider transactions limits actionable insights, but the filings signal ongoing appetite for SPAC vehicles and aerospace consolidation.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 21, 2026

The IPO pipeline on July 21, 2026, reveals a stark contrast between a pre-revenue energy technology company attempting to go public and a clinical-stage biotech filing a registration for a potential reverse merger after a catastrophic regulatory setback. HNO International, Inc. is pursuing an IPO with zero revenue and mounting losses, relying on dilutive equity purchase agreements for survival, which signals a low-quality offering that may struggle to attract institutional demand. Passage BIO, Inc. is effectively filing a 'for sale' sign after its lead drug candidate PBFT02 was dealt a fatal blow by the FDA, triggering a 46% single-day stock collapse and a failed strategic review process where zero of three interested parties made an offer. The aggregate period-over-period data shows no revenue growth across either company (both have zero or de minimis revenue), while insider activity is absent from both filings, suggesting a lack of management conviction. The most critical development is Passage BIO's failed outreach to 148 counterparties, which strongly implies the asset has limited to no value and the S-4 is a precursor to a distressed merger or liquidation. The portfolio-level theme is a 'flight to quality' in the IPO market, where only companies with proven revenue and clear paths to profitability can successfully list, while speculative and pre-revenue companies face severe capital access constraints.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 20, 2026

The IPO pipeline on July 20, 2026, is dominated by a mix of early-stage, high-risk micro-cap offerings and a transformative biotech merger, with no clear sector theme. The most material development is Standard BioTools' all-stock merger with Treeline Biosciences, a $2.5 billion deal that will result in a combined entity with a new name and contingent value rights, signaling a major strategic pivot. However, the pipeline is heavily weighted toward speculative, development-stage companies (RZ Wellness, Londonla Inc.) with no revenue, going-concern risks, and self-underwritten offerings, indicating a surge in low-quality filings. Period-over-period comparisons are largely absent as most filers have no prior operating history, but the lack of insider buying and the prevalence of going-concern warnings create a bearish undercurrent. The Grayscale Worldcoin ETF filing represents a niche but notable push into crypto-based ETFs, while the TCGX Acquisition Corp. SPAC offers a more traditional blank-check structure. Overall, the pipeline shows a bifurcation: one high-quality, high-value merger and a cluster of speculative, high-risk micro-cap IPOs that demand extreme caution.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 17, 2026

The IPO pipeline on July 17, 2026, is heavily concentrated in pre-revenue biopharmaceutical and life sciences companies, with 7 of 8 filings (NuvOx, Latigo, Tivic/Valion, TG-17, Biovie, Alpha Modus, Propanc) coming from this sector. A common theme across these issuers is significant accumulated deficits, negative cash flows, and complex capital structures involving multiple series of convertible preferred stock, warrants, and related-party debt. The lone non-biotech filing is an S-4 merger registration for Bank First Corp's acquisition of PSB Holdings, representing a more mature, revenue-generating entity. Period-over-period data from the filings reveals that all biotech issuers are pre-revenue with no YoY revenue growth, and their net losses are widening (e.g., Biovie's net loss of $12.5M for the nine months ended March 31, 2026). Insider trading activity is absent in these filings, but forward-looking statements uniformly highlight going concern risks and reliance on future financing. The most critical development is the sheer volume of biotech IPOs hitting the market on the same day, which could signal a sector-wide push to access public markets amid a favorable window, but also raises concerns about quality and investor selectivity.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 16, 2026

The IPO pipeline for July 16, 2026, is dominated by the S-1 filing of Phalanx Acquisition Corp I, a blank-check company targeting the real estate & construction sector. As a SPAC with no operating history, the filing provides no period-over-period comparisons, insider trading activity, or capital allocation data, limiting quantitative trend analysis. The offering includes multiple redemption scenarios (0% to 100%) and an over-allotment option, indicating flexibility in capital raising. The company's Cayman Islands incorporation and Puerto Rico address suggest a focus on non-US or tax-advantaged structures. The neutral sentiment and moderate materiality (5/10) reflect the early-stage nature of the filing, with no forward-looking guidance or financial metrics to evaluate. This filing represents a single data point in the IPO pipeline, with no sector-wide patterns or comparative insights available from other registrations.

1 high priority 1 total filings